ArticleBMC cancer2026
Oncolytic adenovirus type 11-induced ferroptosis of esophageal squamous cell carcinoma cells involves in mitochondrial impairment and the mTOR pathway.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHuman adenovirus type 11 (HAdV-11) has several advantages compared with human adenovirus type 5 (HAdV-5), including improved infectivity of tumor cells and the potential for intravenous delivery. Our previous study demonstrated that HAdV-11 efficiently infected various human cancer cell lines including esophageal squamous cell carcinoma (ESCC) cell lines, however the cytotoxicity was not effective in some cell lines. The underlying functional mechanisms for this discrepancy are not clear.
methodsCell viability was assessed using an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2 H-tetrazolium (MTS) assay, and viral replication was quantified by tissue culture infectious dose 50 (TCID50) and quantitative polymerase chain reaction (qPCR). Flow cytometry was employed to analyze apoptosis, mitochondrial reactive oxygen species, lipid oxidation, mitochondrial mass, mitochondrial membrane potential, and intracellular Fe²⁺ levels. Transmission electron microscopy was used for ultrastructural analysis. Protein expression and mitochondrial localization were evaluated by Western blotting and immunofluorescence staining, while reduced glutathione levels were measured using a commercial assay kit.
resultsWe report here that HAdV-11 exerts its anti-ESCC effects via two pathways. Firstly, via the mitochondrial pathway, HAdV-11 promotes mitochondrial fission, thereby enhancing mitophagy, suppressing glutathione peroxidase 4 expression, and increasing lipid peroxidation, which ultimately induces ferroptosis; interestingly, HAdV-11-induced mitophagy attenuates ferroptosis in this context. Secondly, HAdV-11 triggers both mitophagy and ferroptosis through the mammalian target of rapamycin (mTOR) pathway. Our findings indicate that mitochondrial fission and mTOR signaling are closely associated with HAdV-11-induced cytotoxicity in ESCC cells.
conclusionsHAdV-11-induced ferroptosis in ESCC cells involves mitochondrial impairment and the mTOR pathway. These findings provide insights into HAdV-11’s oncolytic mechanisms and suggest strategies for enhancing its therapeutic efficacy in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.